Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are used to reduce low‐density lipoprotein (LDL) cholesterol. PCSK9i use after initiation, as well as persistence with or alterations to other LDL‐lowering therapy after PCSK9i initiation, is not well understood. METHODS A...

Descripción completa

Detalles Bibliográficos
Autores principales: Rymer, Jennifer A., Mues, Katherine E., Monda, Keri L., Bratton, Emily W., Wirtz, Heidi S., Okerson, Ted, Overman, Robert A., Brookhart, M. Alan, Muntner, Paul, Wang, Tracy Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428552/
https://www.ncbi.nlm.nih.gov/pubmed/32326795
http://dx.doi.org/10.1161/JAHA.119.014347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428552/
https://www.ncbi.nlm.nih.gov/pubmed/32326795
http://dx.doi.org/10.1161/JAHA.119.014347

Ejemplares similares